[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623810":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":94,"collaborators":46,"id":96,"slug":46,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":46,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":46,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":46,"overallStatus":63,"whyStopped":46,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Shanghai Argo Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"BW-50218 Dose 1","EXPERIMENTAL","Single dose of BW-50218 injection (Dose 1).",[13],"Drug: BW-50218 Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"BW-50218 Dose 2","Single dose of BW-50218 injection (Dose 2).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"BW-50218 Dose 3","Single dose of BW-50218 injection (Dose 3).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"BW-50218 Dose 4","Single dose of BW-50218 injection (Dose 4).",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"BW-50218 Dose 5","Single dose of BW-50218 injection (Dose 5).",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"BW-50218 Dose 6","Single dose of BW-50218 injection (Dose 6).",[13],{"label":35,"type":36,"description":37,"interventionNames":38},"Saline Placebo","PLACEBO_COMPARATOR","Single dose of Saline Placebo",[39],"Drug: Saline (0.9% NaCl)",[41,47],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","BW-50218 Injection","Solution for injection",[9,15,19,23,27,31],null,{"type":42,"name":48,"description":44,"armGroupLabels":49,"otherNames":46},"Saline (0.9% NaCl)",[35],[51],{"name":52,"affiliation":5,"role":53},"Yuqiong Li, MD","STUDY_DIRECTOR",[55],{"name":56,"role":57,"phone":58,"phoneExt":46,"email":59},"Zhi Hua","CONTACT","+86 185 1618 7545","zhi.hua@argobiopharma.com",[61,79],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"CMAX Clinical Research Pty Ltd","RECRUITING","Adelaide","South Australia","5000","Australia",{"type":69,"coordinates":70},"Point",[71,72],138.59863,-34.92866,{"lat":72,"lon":71},[75],{"name":76,"role":57,"phone":77,"phoneExt":46,"email":78},"Sarada Radha","+61 8 7088 7900","Sarada.Radha@cmax.com.au",{"facility":80,"status":63,"city":81,"state":82,"zip":83,"country":67,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Linear Early Fhase Limited","Nedlands","Western Australia","6009",{"type":69,"coordinates":85},[86,87],115.8073,-31.98184,{"lat":87,"lon":86},[90],{"name":91,"role":57,"phone":92,"phoneExt":46,"email":93},"Jasmine Cahill Loring","+61 8 6382 5100","jloring@linear.org.au",{"type":95,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR","100623810",false,"NCT07401472","Study of BW-50218 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants","Inclusion Criteria:\n\n* Capable of providing written informed consent and complying with all study procedures for the duration of the study.\n* Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.\n* Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.\n* Male participants with partners of childbearing potential must agree to use effective contraception.\n\nExclusion Criteria:\n\n* Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.\n* Recent hospitalization or a significant acute medical event.\n* History of cancer or any long-term medical condition that the study doctor considers clinically relevant.\n* Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.\n* Positive test for hepatitis B, hepatitis C, or HIV.",true,"ALL","18 Years","65 Years",{"count":107,"type":108},60,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants",[114],"Healthy Participants Study","2026-06-23",{"date":117,"type":118},"2026-06-24","ACTUAL",{"date":120,"type":118},"2026-03-12",{"date":122,"type":108},"2027-06-30",{"name":5,"class":6},2]